The results suggest that certain C27OAs might be developed as specific TNF-related apoptosis-inducing ligand (TRAIL) sensitizers and used as chemotherapy agents in glioblastoma patients with low levels of caspase-8 or p53 activity. The gene discussed is TNFSF10; the disease is glioblastoma.